Important Information
The most commonly reported ocular side effect was stinging and burning.

BETIMOL® is contraindicated in patients with overt heart failure, cardiogenic shock, sinus bradycardia, second- or third-degree atrioventricular block, bronchial asthma or history of bronchial asthma, severe chronic obstructive pulmonary disease, or hypersensitivity to any component of this product.

  1. DuBiner, B, Harvey, MD, Hill, Richard, MD, Kaufman, Herbert, MD, et al. Timolol Hemihydrate vs Timolol Maleate to Treat Ocular Hypertension and Open-Angle Glaucoma. American Journal of Ophthalmology, 1996.
  2. Stewart,W, Leland TM, Cate, EA, Stewart, JA. Efficacy and Safety of Timolol Solution Once Daily versus Timolol Gel in Treating Elevated Intraocular Pressure. Journal of Glaucoma, 1998.
  3. Stewart, C, William, MD, Day, G, Douglas, MD, Sharpe, D, Elizabeth, MD, Dubiner, B, Harvey, MD, Holmes, T, Keri, BS and Stewart, A, Jeanette, RN. Efficacy and Safety of Timolol Solution Once Daily vs. Timolol Gel Added to Latanoprost. American Journal of Ophthalmology, 1999.

BETIMOL® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

© VISTAKON® Pharmaceuticals, LLC.

This site is published by VISTAKON® Pharmaceuticals, LLC, which is solely responsible for its content.
It is intended for use by residents of the United States.
BETIMOL® is a registered trademark of Santen Pharmaceutical Co., LTD.santen, and marketed by VISTAKON® Pharmaceuticals, LLC.

VISTAKON® is a registered trademark of VISTAKON® Pharmaceuticals, LLC. vistakon

Last Modified: 05/03/13

2707BE-013